Advertisement

Topics

Amgen’s new migraine drug will cost 30 percent less than Wall Street expected

19:01 EDT 17 May 2018 | STAT

Amgen's decision to undercut expectations comes as the drug industry is being forced to rethink its pricing practices.

Original Article: Amgen’s new migraine drug will cost 30 percent less than Wall Street expected

NEXT ARTICLE

More From BioPortfolio on "Amgen’s new migraine drug will cost 30 percent less than Wall Street expected"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...